🔗 Visit the ClinicalTrials.gov page for NCT01217437
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | The rationale for targeted therapies in medulloblastoma. | Neuro Oncol | 2013 | 0.92 |
| 2 | Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. | Childs Nerv Syst | 2013 | 0.89 |
| 3 | Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. | Br J Cancer | 2012 | 0.84 |
| 4 | Immunotherapy in pediatric malignancies: current status and future perspectives. | Future Oncol | 2014 | 0.78 |
| 5 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |